Hydronidone for long-term treatment of hepatitis B scarring
Treatments studied
Part of Digestive system clinical trials.
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have hepatitis B with liver scarring (fibrosis) and be able to join this Phase 3 study protocol
- Be willing to complete the main treatment course and attend the final study visit
- Understand the study and sign consent, with good ability to communicate and follow study visits and rules
- Must not have a major liver “endpoint” event happen during the Phase 3 trial period (serious progression or complications)
- Not have other cancers (except liver cancer) with an expected survival under 1 year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a long-term treatment with hydronidone capsules to see if it can help reduce liver scarring (fibrosis) in people with chronic hepatitis B. It aims to improve liver health and prevent progression to more serious liver disease.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
This Phase 2 trial tests an injection medicine (F573) to see if it can improve people with liver injury, drug-related liver damage, or liver failure. You may be screened with blood tests, liver stiffness measurements, and possibly symptom checks.
This Phase 3 study tests medicines to see whether they can reduce liver scarring (fibrosis) in people with long-term hepatitis C. If you qualify, you may receive the study treatment and be monitored over time to see how your liver is affected.
This Phase 1 study tests a stem cell product to see if it is safe and how it affects people with worsening hepatitis B-related cirrhosis. It may help researchers understand whether the treatment could improve liver function in this stage of illness.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.